Vertex Pharmaceuticals Bolsa (NASDAQ: VRTX)

Últimas noticias sobre Vertex Pharmaceuticals (NASDAQ:VRTX) Bolsa

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Equities

News

Markets

ETFs

$BTC

ARKF

ARKG

ARKK

ARKW

COIN

EXAS

PLTR

PSNL

VRTX

El miércoles, Cathie Wood, a la cabeza de Ark Invest, realizó algunas operaciones significativas, siendo las más destacadas las de Coinbase Global Inc (NASDAQ:COIN) y Palantir Technologies Inc (NYSE:

Movimientos clave de Cathie Wood: ¿qué hay detrás de las últimas operaciones de Ark Invest?

BLDR

SERV

VKTX

Jim Cramer analiza VRTX, SERV, BLDR y VKTX en &#39;Mad Money&#39;. Descubre por qué algunas acciones suben mientras otras caen.

Jim Cramer analiza las mejores oportunidades de inversión en &#39;Mad Money&#39;

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals Inc

VERTEX PHARMACEUTICALS ORD

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 5 years by 5.11% on an annualized basis producing an average annual return of 18.8%. Currently, Vertex Pharmaceuticals has a market capitalization of $122.70 billion. 
Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 5 years ago, it would be worth $2,431.96 today based on a price of $475.40 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730143810_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 5 Years

Former President Donald Trump previously spent four years in the White House, which could help investors know which stocks and sectors could benefit under a second term if he wins the<a href="https://www.benzinga.com/topic/2024-election"> 2024 presidential election.</a>
Here's a look back at the top performing stocks in 2017, Trump's first year in the White House.
Top Performing 2017 Stocks: The stock markets saw impressive gains in 2017, which were among the best ever for a president's <a href="https://www.benzinga.com/markets/futures/18/01/11066769/the-stock-markets-rally-under-trump-among-the-best-ever-heres-how-his">first year in the White House.</a>
The S&amp;P 500, which is tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), gained 21.7% in 2017, an impressive gain to the +12.0% increase in 2016, as presidential election years have historically produced outperformance to other years.
With the potential for Trump to be re-elected in 2024, here's a look back at the top 10 performing stocks in the S&amp;P 500 from 2017, as reported previously by <a href="https://www.marketwatch.com/story/biggest-sp-500-winners-and-losers-of-2017-tech-health-care-and-home-builders-lead-2017-12-29">Marketwatch</a>.
<ol>
<li>NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>): +132%, utilities</li>
<li>Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>): +131%, health care</li>
<li>Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>): +103%, health care</li>
<li>Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>): +95%, consumer discretionary</li>
<li>Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): +89%, industrials</li>
<li>Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>): +88%, technology</li>
<li>D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>): +87%, consumer discretionary, homebuilders</li>
<li>PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): +87%, technology</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>): +81%, technology</li>
<li>Pulte Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>): 81%, consumer discretionary, homebuilders</li>
</ol>
The top 10 stocks in 2017 likely saw gains related to reasons that didn't have to do with Trump being president, but there are also some common themes and some potential connections to the former president.
The results show that health care, consumer discretionary and technology stocks were among the top-performing sectors.
Of particular note is Micron and Nvidia, both ranking in the top 10, a potential positive for the semiconductor sector under a Trump presidency.
Another key trend could be two homebuilders ranking among the top 10 best-performing stocks in 2017. Homebuilders have been a popular sector to watch under a possible Kamala Harris win with the current vice president and Trump running on a platform of <a href="https://www.benzinga.com/general/politics/24/08/40424431/harris-warns-trump-tax-plan-will-devastate-americans-vows-to-go-after-bad-actors-behind-food-pri">building more homes</a> for the middle class.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent102824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: While past results don't guarantee future results, sometimes market trends can show patterns and signs of what to come.
Based on the top-performing stocks in 2017, investors may want to prepare for some <a href="https://www.benzinga.com/markets/equities/24/10/41213583/what-a-trump-win-could-mean-for-financial-energy-stocks-lessons-from-2016">exposure to health care</a>, utilities, semiconductors and homebuilders if Trump wins the 2024 election.
With less than two weeks until the 2024 election, investors are likely positioning their portfolios based on a Trump or Harris win in some regards. With a close election predicted, investors may want to look to sectors that could benefit under either candidate.
Freedom Capital Markets Chief Global Strategist Jay Woods previously shared some <a href="https://www.benzinga.com/etfs/sector-etfs/24/08/40515453/exclusive-trump-or-harris-12-stocks-2-etfs-could-win-no-matter-whos-president-says-market-strate">sectors and stocks to watch</a> with Benzinga that could benefit regardless of whether Trump or Harris wins the 2024 election.
Woods named defense stocks and cybersecurity stocks as two of the top sectors to watch ahead of the 2024 election.
"I think you've got to watch this sector closely," Woods said of the defense sector.
Woods said defense stocks could continue to benefit from geopolitical concerns and a lot of bad things happening in the world.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/10/41534317/if-trump-wins-2024-election-in-landslide-bettors-could-make-5x-20x-their-bets-at-uk-sports">If Trump Wins 2024 Election In Landslide, Bettors Could Make 5X, 20X Their Bets At UK Sportsbook</a></li>
</ul>
Photo: Shutterstock

Politics

ALGN

NVDA

PYPL

WYNN

These 10 Stocks Were The Best S&P 500 Performers In 2017 When Trump Was President: Will History Repeat Itself?

- New data on povetacicept 80 mg SC Q4 weeks in IgA nephropathy shows mean UPCR reduction from baseline of 66% observed at 48 weeks, associated with stable renal function (eGFR) and 63% achieving clinical remission --
- First proteinuria data on povetacicept in primary membranous nephropathy shows mean UPCR reduction from baseline of 62% at 24 weeks –
- Global Phase 3 RAINIER trial of povetacicept in IgA nephropathy now underway –
– Enrollment and dosing ongoing in Phase 3 portion of the global Phase 2/3 pivotal clinical trial of inaxaplin for the treatment of APOL1-mediated kidney disease –
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vrtx.com%2F&amp;esheet=54141927&amp;newsitemid=20241024004527&amp;lan=en-US&amp;anchor=Vertex+Pharmaceuticals+Incorporated&amp;index=1&amp;md5=497f5e92c05e7baff91083819e2b1884">Vertex Pharmaceuticals Incorporated</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) today provided updates on multiple kidney diseases in its pipeline including IgA nephropathy (IgAN), primary membranous nephropathy (pMN), and APOL1-mediated kidney disease (AMKD). These updates demonstrate the transformative potential of Vertex's investigational therapies in multiple serious kidney diseases, and include positive new data on povetacicept, a dual inhibitor of the BAFF and APRIL pathways, in IgAN and pMN, presented at the American Society of Nephrology's (ASN) Kidney Week Congress on October 23-27 in San Diego, California.

Biotech

General

Vertex Provides Updates On Multiple Kidney Programs At The American Society Of Nephrology Annual Kidney Week Congress; First Proteinuria Data On Povetacicept In Primary Membranous Nephropathy Shows Mean UPCR Reduction From Baseline Of 62% At 24 Weeks

Vertex Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NYSE">VRTX</a>) short percent of float has fallen 5.95% since its last report. The company recently reported that it has 4.08 million shares sold short, which is 1.58% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Vertex Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729540823_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 5.33%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Vertex Pharmaceuticals's Recent Short Interest

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and maintains $600 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Vertex Pharmaceuticals, Maintains $600 Price Target

Deep-pocketed investors have adopted a bullish approach towards Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in VRTX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Vertex Pharmaceuticals. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 55% leaning bullish and 22% bearish. Among these notable options, 3 are puts, totaling $78,221, and 6 are calls, amounting to $288,843.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $400.0 to $500.0 for Vertex Pharmaceuticals during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 362.25 with a total volume of 254.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Vertex Pharmaceuticals's big money trades within a strike price range of $400.0 to $500.0 over the last 30 days.
<h3>Vertex Pharmaceuticals Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729281688_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$40.1</td>
<td>$35.4</td>
<td>$38.45</td>
<td>$500.00</td>
<td>$76.9K</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$129.7</td>
<td>$127.0</td>
<td>$127.0</td>
<td>$400.00</td>
<td>$50.8K</td>
<td style="text-align: right;">47</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$33.9</td>
<td>$29.0</td>
<td>$31.0</td>
<td>$480.00</td>
<td>$46.5K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">15</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/25/24</td>
<td>$7.7</td>
<td>$7.5</td>
<td>$7.6</td>
<td>$490.00</td>
<td>$41.8K</td>
<td style="text-align: right;">77</td>
<td style="text-align: right;">61</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$38.4</td>
<td>$37.0</td>
<td>$38.45</td>
<td>$500.00</td>
<td>$38.4K</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">30</td>
</tr>
</tbody>
</table>

<h3>About Vertex Pharmaceuticals</h3>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Present Market Standing of Vertex Pharmaceuticals</h3>
<ul>
<li>Currently trading with a volume of 1,095,504, the VRTX's price is down by -3.04%, now at $483.59. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 17 days.</li>
</ul>
<h3>What The Experts Say On Vertex Pharmaceuticals</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $471.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Vertex Pharmaceuticals with a target price of $541. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Vertex Pharmaceuticals with a target price of $425. 
&#x2A; An analyst from RBC Capital has decided to maintain their Sector Perform rating on Vertex Pharmaceuticals, which currently sits at a price target of $437. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Vertex Pharmaceuticals, targeting a price of $474. 
&#x2A; An analyst from Scotiabank has revised its rating downward to Sector Perform, adjusting the price target to $480. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Market Whales and Their Recent Bets on VRTX Options

-- Phase 3 abstract selected for presentation in "Best Abstract" session --
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vrtx.com&amp;esheet=54137554&amp;newsitemid=20241017447532&amp;lan=en-US&amp;anchor=Vertex+Pharmaceuticals+Incorporated&amp;index=1&amp;md5=6c6ece64284e740aec404ef03c805cb0">Vertex Pharmaceuticals Incorporated</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the American Society of Anesthesiologists (ASA), taking place from October 18-22, 2024 in Philadelphia, Pennsylvania.
<ul>
<li>Abstract A1187 — "Randomized, Placebo-Controlled, Phase 3 Trials of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor for Treatment of Acute Pain After Abdominoplasty or Bunionectomy" will be presented as an oral presentation on Sunday, October 20, during the "Best Abstract" session, which runs from 8:00-11:00 a.m. ET, as well as the Education session which runs on Monday, October 21, from 1:30-2:30 p.m. ET.</li>
<li>Abstract A2074 — "A Phase 3, Single-Arm Study of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor For Treatment of Acute Pain From Surgical and Non-surgical Conditions" will be presented in a poster session on Saturday, October 19, from 10:00-11:30 a.m. ET.</li>
</ul>
This will be the first time the suzetrigine Phase 3 data will be presented to the medical community following the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.vrtx.com%2Fnews-releases%2Fnews-release-details%2Fvertex-announces-positive-results-vx-548-phase-3-program&amp;esheet=54137554&amp;newsitemid=20241017447532&amp;lan=en-US&amp;anchor=January+2024&amp;index=2&amp;md5=4170e8d07ce4d104c426500079dbc880">January 2024</a> announcement that the Phase 3 trials were positive. The Phase 3 program included two randomized, double-blind, placebo-controlled trials, one following abdominoplasty surgery and one following bunionectomy surgery, as well as a single arm safety and effectiveness study which enrolled patients with a broad range of surgical and non-surgical pain conditions. Results from all three studies demonstrate compelling and consistent efficacy and safety across multiple acute pain conditions and settings.

Vertex To Present Phase 3 Data Highlighting Suzetrigine's Potential As A First-In-Class, Highly Selective Pain Signal Inhibitor At The American Society Of Anesthesiologists Annual Meeting

In the preceding three months, 19 analysts have released ratings for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $498.84, a high estimate of $600.00, and a low estimate of $376.00. Observing a 6.49% increase, the current average has risen from the previous average price target of $468.44. 
<img src="https://www.benzinga.com/files/images/story/2024/1729188046_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Vertex Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$562.00</td>
<td>$477.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$480.00</td>
<td>-</td>
</tr>
<tr>
<td>Ying Huang</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$541.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$437.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$425.00</td>
<td>$431.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$474.00</td>
<td>$462.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$431.00</td>
<td>$431.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$550.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$510.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$508.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$509.00</td>
<td>$472.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$558.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$535.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Sell</td>
<td>$376.00</td>
<td>$371.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$440.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Vertex Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Vertex Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Vertex Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>About Vertex Pharmaceuticals</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Unraveling the Financial Story of Vertex Pharmaceuticals</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Vertex Pharmaceuticals displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 6.11%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Vertex Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -135.83%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Vertex Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -21.57%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -16.32%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.06.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (19 Ratings)

UBS analyst Colin Bristow maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and raises the price target from $477 to $562.

UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $562

Scotiabank analyst Greg Harrison initiates coverage on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform rating and announces Price Target of $480.

Initiation

Scotiabank Initiates Coverage On Vertex Pharmaceuticals with Sector Perform Rating, Announces Price Target of $480

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 5 years by 6.32% on an annualized basis producing an average annual return of 20.45%. Currently, Vertex Pharmaceuticals has a market capitalization of $125.03 billion. 
Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 5 years ago, it would be worth $2,639.51 today based on a price of $484.43 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729087223_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today

Whales with a lot of money to spend have taken a noticeably bullish stance on Vertex Pharmaceuticals.
Looking at options history for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations and 46% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $626,461 and 4, calls, for a total amount of $352,063.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $410.0 to $500.0 for Vertex Pharmaceuticals over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Vertex Pharmaceuticals stands at 251.25, with a total volume reaching 5,670.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Vertex Pharmaceuticals, situated within the strike price corridor from $410.0 to $500.0, throughout the last 30 days.
<h3>Vertex Pharmaceuticals 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729018852_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/25/24</td>
<td>$7.8</td>
<td>$7.2</td>
<td>$7.5</td>
<td>$480.00</td>
<td>$231.7K</td>
<td style="text-align: right;">0</td>
<td>1.0K</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$83.2</td>
<td>$76.5</td>
<td>$78.8</td>
<td>$410.00</td>
<td>$157.6K</td>
<td style="text-align: right;">0</td>
<td>20</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/25/24</td>
<td>$3.9</td>
<td>$2.65</td>
<td>$4.0</td>
<td>$500.00</td>
<td>$122.4K</td>
<td style="text-align: right;">11</td>
<td>501</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$10.1</td>
<td>$8.4</td>
<td>$10.1</td>
<td>$460.00</td>
<td>$101.0K</td>
<td style="text-align: right;">29</td>
<td>95</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/25/24</td>
<td>$6.0</td>
<td>$5.1</td>
<td>$6.0</td>
<td>$480.00</td>
<td>$70.2K</td>
<td style="text-align: right;">0</td>
<td>299</td>
</tr>
</tbody>
</table>

<h3>About Vertex Pharmaceuticals</h3>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Having examined the options trading patterns of Vertex Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Vertex Pharmaceuticals</h3>
<ul>
<li>Currently trading with a volume of 727,981, the VRTX's price is down by -0.36%, now at $483.07. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 20 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Vertex Pharmaceuticals options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Check Out What Whales Are Doing With VRTX

B of A Securities analyst Ying Huang maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and lowers the price target from $550 to $541.

B of A Securities Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $541

Raymond James analyst Danielle Brill reinstates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Market Perform.

Raymond James Reinstates Market Perform on Vertex Pharmaceuticals

The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare &amp; Medicaid Services (CMS), has released a Request for Information (RFI) regarding a new initiative to lower prescription drug costs for Medicare recipients.
The Medicare $2 Drug List Model, developed under President Biden&#8217;s Executive Order 14087, seeks to offer certain generic drugs for a fixed copayment of no more than $2 per month.
This initiative targets commonly prescribed drugs for conditions like high cholesterol and high blood pressure.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">Novo Nordisk&#8217;s Ozempic Might Be Among 2027 Medicare Price Negotiation Targets</a>.
The Center for Medicare and Medicaid Innovation (Innovation Center) has designed the Medicare $2 Drug List Model to test whether simplifying access to affordable, clinically important generics will improve health outcomes, improve medication adherence, and boost overall satisfaction with the Medicare Part D program.
These drugs, which would not be subject to typical utilization management requirements, could be available at all participating pharmacies as early as January 2027.
The initial list of <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/biden-harris-administration-takes-next-step-proposed-model-lower-prescription-drug-costs-people" rel="noreferrer noopener">drugs</a> for the $2 Drug List Model has been carefully developed through a rigorous process. It incorporates input from physicians, pharmacists, and health policy experts to ensure that the selected medications address common conditions for Medicare recipients.
The concept of a fixed-cost drug list is not new, with many retail pharmacies already offering generic medications at low, standardized prices.
However, the Medicare $2 Drug List Model will be tailored specifically to Medicare recipients.
Last week,&nbsp;the HHS released final guidance for the second &nbsp;Medicare Drug Price <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Negotiation Program cycle</a>.
This initiative&nbsp;<a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-releases-final-guidance-second-cycle-historic-medicare-drug-price-negotiation-program" rel="noreferrer noopener">aims</a> to provide lower drug prices starting in 2026 and 2027.
The first round of negotiations focused on ten specific drugs. When the new prices take effect in 2026, Medicare recipients should save approximately $1.5 billion in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" rel="noreferrer noopener">out-of-pocket costs</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41256266/is-the-iphone-losing-its-buzz-among-teens-piper-sandler-finds-out" target="_blank" rel="noreferrer noopener">Is The iPhone Losing Its Buzz Among Teens? Piper Sandler Finds Out</a></li>
</ul>
Image via Shutterstock

Government

Health Care

AMGN

BMRN

GILD

REGN

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $425 to $437.

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $437

Cathie Wood&#8217;s Ark Invest made significant trades in Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Robinhood Markets Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), and Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>).
The Amazon Trade: Ark Invest purchased 76,505 shares of Amazon, despite recent concerns about the company&#8217;s growth trajectory. The trade was executed through its flagship ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>).
This move came after <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41234873/amazon-stock-downgrade-by-wells-fargo-a-bearish-signal-on-growth-concerns">Wells Fargo downgraded</a> Amazon from Overweight to Equal-Weight, citing slowing growth and stiffer competition. The value of this trade, based on the closing price of $182.72, is approximately $13.98 million.
Amazon shares dropped Monday after Wells Fargo downgraded the stock, citing slowing growth and competition. The sell-off was <a href="https://www.benzinga.com/news/24/10/41216248/amazon-stock-is-sliding-monday-whats-going-on">also fueled</a> by a federal judge&#8217;s ruling allowing the FTC&#8217;s antitrust lawsuit against Amazon to proceed.
The Robinhood Trade: Ark Invest sold a total of 1,421,431 shares of Robinhood across three of its ETFs i.e. ARK Innovation ETF, ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) and Ark Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>). This decision came despite Robinhood&#8217;s recent announcement of its first investor day and the introduction of <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41236863/robinhood-eyes-major-growth-with-new-trading-features-while-coinbase-rides-crypto-s">new trading features</a>. The value of this trade, based on the closing price of $25.61, is approximately $36.4 million.
The Coinbase Trade: Ark Invest bought 12,994 shares of Coinbase through its ARKF ETF. This move aligns with the recent surge in Coinbase shares following the company&#8217;s announcement to <a href="https://www.benzinga.com/news/24/10/41191796/why-coinbase-global-shares-are-trading-higher-today">adjust its service offerings</a> in response to new European regulatory requirements. The value of this trade, based on the closing price of $167.69, is approximately $2.18 million.
See Also: <a href="https://www.benzinga.com/news/24/10/41208397/this-alibaba-analyst-turns-bullish-here-are-top-5-upgrades-for-monday?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">This Alibaba Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday</a> 
Other Key Trades:
<ul>
<li>Ark purchased 2,365 shares of Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) through its ARKW ETF. The Meta trade was valued at $1.4 million. On Tuesday, Meta shares closed 1.4% higher at $592.89.</li>
<li>Ark Invest sold shares of Veeva Systems Inc (VEEV) and shares of Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) through its ARKG ETF. It bought shares of Recursion Pharmaceuticals Inc (RXRX) and shares of 10X Genomics Inc (TXG). </li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41221351/elon-musks-theory-gains-ground-polymarket-odds-soar-for-nick-szabo-being-named-bitcoin-cre?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Theory Gains Ground? Polymarket Odds Soar For Nick Szabo Being Named Bitcoin Creator Satoshi Nakamoto In HBO Documentary</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

AMZN

HOOD

Cathie Wood's Ark Invest Trades: Bets $14M On Amazon Shares — Dumps Robinhood Stock Worth $36M, Embraces Coinbase And Meta

Cantor Fitzgerald analyst Olivia Brayer reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and maintains $480 price target.

Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $480 Price Target

Goldman Sachs upgraded its 12-month price target for the S&amp;P 500 index from 5,600 to 6,300, driven by stronger-than-expected corporate earnings heading into the third quarter and robust demand <a href="https://www.benzinga.com/topic/artificial-intelligence">for artificial intelligence technologies. </a>
The revision, outlined in a report led by U.S. equity strategist David Kostin, reflects optimism around earnings-per-share (EPS) growth and margin expansion, particularly in key sectors like technology and healthcare.
The S&amp;P 500, which tracks the largest 500 U.S. corporations through the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), is currently trading less than 1% below its all-time high.
<h3 class="wp-block-heading">S&amp;P 500 Earnings Forecasts Upwardly Revised</h3>
Goldman Sachs now projects the S&amp;P 500&#8217;s earnings per share to rise to $268 in 2025, representing an 11% year-over-year increase. 
&#8220;The primary driver of the upward revision to our 2025 EPS estimate is greater margin expansion,&#8221; analysts wrote. 
This is up from the bank&#8217;s previous estimate of $256, which forecasted just 6% growth. For 2026, the investment bank forecasts further EPS growth to $288, or 7%, continuing a healthy upward trajectory.
For the current year, Goldman Sachs maintains its full-year EPS forecast of $241 for the S&amp;P 500, reflecting an 8% year-over-year growth, consistent with prior guidance.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Year</th>
<th>Goldman Sachs&#8217; S&amp;P 500 EPS Forecast</th>
<th>Growth Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>2024</td>
<td>$241</td>
<td>+8%</td>
</tr>
<tr>
<td>2025</td>
<td>$268</td>
<td>+11%</td>
</tr>
<tr>
<td>2026</td>
<td>$288</td>
<td>+7%</td>
</tr>
</tbody>
</table>
</figure>
Goldman Sachs' earnings forecasts are supported by steady macroeconomic growth expectations. 
The firm's economists predict that U.S. GDP will grow by 2.3% in 2025, followed by a 2.0% expansion in 2026. 
Despite inflationary pressures, the bank expects companies to maintain pricing power, which should help them offset rising labor and input costs.
<h3 class="wp-block-heading">AI and Semiconductor Recovery Boost IT Sector Outlook</h3>
A key driver behind Goldman Sachs' more bullish outlook is the increasing role of AI and the recovery in the semiconductor sector. 
According to the report, semiconductor shipments—excluding memory chips—are currently about 10% below their historical trend. 
As this shortfall reverses, the firm anticipates stronger margins for the industry, contributing approximately $7, or 20%, of the S&amp;P 500&#8217;s EPS growth in 2025.
The investment bank also highlighted the ongoing strength in mega-cap tech firms, such as Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
These companies have consistently delivered quarterly earnings surprises, with an average beat of 9% over the past four quarters.
Goldman Sachs noted that &#8220;while the magnitude of beats may moderate,&#8221; there is &#8220;strong ongoing AI demand that should benefit these stocks.&#8221;
<h3 class="wp-block-heading">Margin Expansion To Power 2025 Gains</h3>
Goldman Sachs has revised its expectations for S&amp;P 500 net margin expansion in 2025, now forecasting a 78 basis point increase compared to its earlier estimate of just 24 basis points. This enhanced margin outlook stems largely from a more favorable macroeconomic environment, where input costs are expected to rise at a slower pace than the prices charged by companies, thus widening margins.
One key factor behind the forecasted margin gains is the normalization of certain one-off expenses that have weighed heavily on corporate earnings in 2024. 
For instance, in the healthcare sector, companies like Bristol-Myers Squibb Co.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), and Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) were significantly impacted by high R&amp;D-related charges earlier in the year. 
Goldman Sachs predicts these expenses will moderate in 2025, leading to an $83 boost in healthcare margins alone, contributing to a broader EPS uplift.
<h3 class="wp-block-heading">Downside, Upside Scenarios And Short-Term Targets</h3>
If economic growth slows more than expected, the S&amp;P 500's price-to-earnings (P/E) ratio could compress to 18x, which would imply a price target of 5,400—about 6% lower than current levels. Additionally, uncertainty surrounding U.S. monetary policy and the outcome of the 2024 election could lead to increased market volatility.
On the upside, if the P/E ratio remains stable at 22x, the index could climb to 6,600 in the next 12 months. In a more optimistic scenario, where economic growth remains robust and investor sentiment improves, Goldman Sachs suggests the P/E ratio could rise to 23x, pushing the S&amp;P 500 to 6,900 by year-end 2025.
For the remainder of 2024, Goldman Sachs expects the S&amp;P 500 to experience some volatility as investors weigh the implications of the Federal Reserve&#8217;s policy stance and the upcoming presidential election. 
The bank sees limited downside risks and has set a three-month price target of 6,000 for the index, up from a previous target of 5,600. Over the next six months, Goldman expects the index to reach 6,100.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41191633/us-energy-stocks-notch-biggest-weekly-gains-in-2-years-exxon-hits-record-highs-as">US Energy Stocks Notch Biggest Weekly Gains In 2 Years, Exxon Hits Record Highs As Crude Surges To $75 On Israel-Iran Jitters</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Large Cap

Broad U.S. Equity ETFs

Tech

AAPL

GOOG

GOOGL

MSFT

S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and lowers the price target from $431 to $425.

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $425

Goldman's High Growth Investment ratio stocks: EA, AMZN, FANG, etc

Wells Fargo analyst Mohit Bansal has maintained their bullish stance on VRTX stock, giving a Buy rating yesterday. Mohit Bansal has given his Buy r...

Vertex Pharmaceuticals' Promising Market Position and Opioid-Sparing Solution Drive Buy Rating

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with...

Piper Sandler Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and improve treatment options. Given this favorable trend, it could be wise to watch strong pharma stocks such as Vertex Pharmaceuticals (VRTX), Wave Life Sciences (WVE), and Poseida Therapeutics (PSTX). Read more... In 2024, gene therapy is gaining traction, driven by breakthroughs like CRISPR technology and high-cost therapies. Growing regulatory approvals and innovative solutions for rare diseases position gene therapy as a promising investment opportunity in the pharmaceutical landscape.
Amid this favorable backdrop, investors could consider keeping an eye on strong pharma stocks: Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>), Wave Life Sciences Ltd. (<a href="https://stocknews.com/stock/WVE/">WVE</a>), and Poseida Therapeutics, Inc. (<a href="https://stocknews.com/stock/PSTX/">PSTX</a>).
Gene therapy is driving growth in the pharmaceutical industry by addressing complex conditions through innovations like recombinant AAV vectors and peptide-modified AAV capsids. These advancements improve treatment options and patient outcomes, opening market opportunities. Global pharmaceutical revenues are projected to reach $1.16 trillion this year, with a <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">6.2% CAGR</a>, reaching $1.47 trillion by 2028. Also, the global gene therapy market is projected to grow at <a href="https://www.grandviewresearch.com/industry-analysis/gene-therapy-market">a CAGR of 18.9%</a> until 2030.
In addition, gene therapy is revolutionizing biotech innovation by shortening drug development timelines. Enhanced delivery methods and technologies like CRISPR improve precision and efficacy, reigniting interest in the industry. As a result, the pharmaceutical sector is positioned for robust growth, with the global biotechnology market expected to reach $3.88 trillion by 2030, at a <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">CAGR of 14%</a>.
Considering these conducive trends, let's take a look at the fundamentals of the three pharma picks.
Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>)
VRTX is a biotechnology company that develops and commercializes therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO.
On August 7, 2024, VRTX announced a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access CASGEVY. This CRISPR/Cas9 gene-edited therapy is one of the first medicines funded by NHS England's Innovative Medicines Fund.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebit.asp">EBIT</a> margin, VRTX's 40.61% is considerably higher than the 2.64% industry average. Likewise, its 27.99% trailing-12-month levered FCF margin is significantly higher than the 1.44% industry average. Furthermore, its 0.51x trailing-12-month asset turnover ratio is 24.3% higher than the 0.41x industry average.
VRTX's net revenues for the fiscal second quarter that ended on June 30, 2024, increased 6.1% year-over-year to $2.64 billion. Its interest income grew 8.2% from the prior year's quarter to $156.50 million. Furthermore, as of June 30, 2024, the company's total liabilities and shareholders' equity stood at $20.13 billion, compared to $22.73 billion as of December 31, 2023.
Street expects VRTX's net product revenues for the quarter ended September 30, 2024, to increase 8.4% year-over-year to $2.69 billion. Its EPS for the same quarter is expected to grow 1.3% year-over-year to $4.13. It surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, VRTX's stock has gained 31.2% to close the last trading session at $474.91.
VRTX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect strong prospects. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It is ranked #72 out of 328 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. It has a B grade for Stability. <a href="https://stocknews.com/stock/VRTX/">Click here</a> to see VRTX's Growth, Value, Momentum, Sentiment, and Quality ratings.
Wave Life Sciences Ltd. (<a href="https://stocknews.com/stock/WVE/">WVE</a>) 
Based in Singapore, WVE is a clinical-stage genetic medicine company that designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug development platform. It is developing oligonucleotides that target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, and restore the production of functional proteins.
On October 16, 2024, WVE announced the first-ever therapeutic RNA editing in humans in its RestorAATion-2 trial for alpha-1 antitrypsin deficiency (AATD). The single dose of WVE-006 restored wild-type M-AAT protein, offering a potential treatment for AATD-related lung and liver disease.
In terms of the trailing-12-month asset turnover ratio, WVE's 0.50x is 22.6% higher than the 0.41x industry average.
WVE's revenue for the second quarter that ended on June 30, 2024, was $19.69 million. For the same quarter, the company's net total other income stood at $2.07 million. Moreover, as of June 30, 2024, the company's total liabilities were $204.42 million, compared to $227.45 million as of December 31, 2023.
WVE surpassed the consensus revenue estimates in three of the trailing four quarters. Over the past nine months, the stock has gained 210% to close the last trading session at $14.54.
WVE's POWR Ratings reflect a robust outlook. It has a B grade for Sentiment. It is ranked #81 out of 161 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry. To see WVE's additional grades for Growth, Value, Momentum, Stability, and Quality, <a href="https://stocknews.com/stock/WVE/">click here</a>.
Poseida Therapeutics, Inc. (<a href="https://stocknews.com/stock/PSTX/">PSTX</a>)
PSTX, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for hematologic malignancies include P-BCMA-ALLO1, P-CD19CD20-ALLO1, P-BCMACD19-ALLO1, and P-CD70-ALLO1.
On October 17, 2024, PSTX announced the nomination of a new allogeneic, dual CAR-T therapy development candidate under its collaboration with Roche, triggering a $15 million milestone payment. This extends PSTX's cash runway into early 2026, with a focus on treating hematologic malignancies, including multiple myeloma.
For the fiscal second quarter (ended June 30, 2024), PSTX's total revenues increased 29.8% year-over-year to $25.97 million. The company's net other income was $2.64 million, up 4% from the previous year's quarter. In addition, the company's total assets came in at $298.69 million, compared to $273.89 million as of December 31, 2023.
Analysts expect PSTX's revenue for the quarter ended September 30, 2024, to increase 73.8% year-over-year to $16.25 million. It surpassed the EPS estimates in three of the trailing four quarters. Over the past six months, PSTX's stock has gained 14.6% to close the last trading session at $2.47.
It's no surprise that PSTX has an overall rating of B, which translates to a Buy in our proprietary POWR Ratings system.
It has a B grade for Value, Sentiment, and Quality. It is ranked #34 in the Medical - Pharmaceuticals industry. Beyond what we stated above, we also have given PSTX grades for Growth, Momentum, and Stability. Get all the PSTX's ratings <a href="https://stocknews.com/stock/PSTX/">here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
VRTX shares were trading at $470.05 per share on Wednesday afternoon, down $4.86 (-1.02%). Year-to-date, VRTX has gained 15.52%, versus a 22.75% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/vrtx-wve-pstx-3-pharma-stocks-to-watch-as-gene-therapy-gains-momentum/>3 Pharma Stocks to Watch as Gene Therapy Gains Momentum</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Pharma Stocks to Watch as Gene Therapy Gains Momentum

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $515.00...

Vertex Pharmaceuticals (VRTX) Gets a Buy from Evercore ISI

Gena Wang, an analyst from Barclays, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated price target rem...

Vertex Pharmaceuticals: Hold Rating Amid Promising Developments and Pending Long-Term Validation

Crispr Therapeutics: Poised For A Major Turnaround

In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price...

Vertex Pharmaceuticals (VRTX) Receives a Hold from Scotiabank

Truist Financial analyst Joon Lee maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company's shares closed las...

Vertex Pharmaceuticals (VRTX) Gets a Buy from Truist Financial

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) and keeping the price target at $5...

Vertex Pharmaceuticals' Strategic Approach to LSR Pain Trial Justifies Buy Rating

ADSK

AXON

BIIB

BLUE

CDNS

CRSP

DLTR

EBAY

FANG

FFIV

FSLR

GDDY

GRMN

INCY

INTC

KEYS

MRNA

MTCH

NCLH

NTAP

ORCL

PODD

PSTX

QCOM

SNPS

TRMB

UBER

ZBRA

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Press Releases

Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England

Vertex to Participate in Upcoming September Investor Conferences

Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference

Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic Fibrosis

Entertainment

Real Estate

The Week in Canadian Press Releases: 10 Stories You Need to See

Vertex to Announce Third Quarter 2024 Financial Results on November 4th

Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting

Comments

Vertex Pharmaceuticals

Noticias

Últimas noticias sobre Vertex Pharmaceuticals (NASDAQ:VRTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL